Related Experiment Videos
Statins and newly diagnosed diabetes
Susan S Jick1, Brian D Bradbury
1Boston Collaborative Drug Surveillance Program, 11 Muzzey Street, Lexington, MA 02421, USA. sjick@bu.edu
British Journal of Clinical Pharmacology
|August 26, 2004
Summary
This study found that statins, a type of HMG Co-A reductase inhibitor, show little to no protective effect against the development of Type 2 diabetes. Further research may be needed to confirm these findings for specific statin types.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes is a growing global health concern.
- HMG Co-A reductase inhibitors (statins) are widely used to manage hyperlipidemia.
- A potential protective effect of statins against Type 2 diabetes has been hypothesized.
Purpose of the Study:
- To evaluate the hypothesized protective effect of statin use on the development of Type 2 diabetes.
- To analyze data from a large UK-based population to assess this relationship.
Main Methods:
- A nested case-control study was conducted using data from the General Practice Research Database (GPRD).
- The study included adults aged 30-79 between 1991 and 2002.
- 588 incident cases of Type 2 diabetes and 2063 matched controls were analyzed.
Main Results:
- Current statin use showed an adjusted odds ratio (OR) of 1.1 (95% CI 0.8, 1.4) compared to non-exposed subjects.
- Pravastatin use alone had an adjusted OR of 0.7 (95% CI 0.4, 1.2), and simvastatin use alone had an OR of 1.0 (95% CI 0.7, 1.3).
- Little evidence for a duration effect was found for simvastatin, with a slight suggestion of long-term protection with pravastatin.
Conclusions:
- The study findings suggest minimal to no protective effect of statins on the development of Type 2 diabetes.
- These results indicate that statins are unlikely to prevent the onset of Type 2 diabetes.
- Further investigation into specific statins and long-term effects may be warranted.